Central Trust Company’s Altimmune ALT Stock Holding History

Central Trust Company’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$7K	–	1181
2021 Q1	$7K	Buy	+500	New	+$8.08K	﹤0.01%	958

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Central Trust Company's ALT Position: Q2 2021 in Review

Central Trust Company sold out of Altimmune (ALT) in Q2 2021, closing a stake of 500 shares — an estimated $7K sold.

Central Trust Company first reported a position in ALT in Q1 2021 and held it in 1 quarter. The position peaked at $7K in Q1 2021. 109 funds tracked by Wall St. Rank hold ALT as of Q2 2021.

Central Trust Company reported no remaining Altimmune position as of Q2 2021 after selling out during the quarter.
Central Trust Company sold 500 Altimmune shares in Q2 2021, an estimated $7K.
Central Trust Company first reported a position in Altimmune in Q1 2021 and held it in 1 quarter.
Central Trust Company's Altimmune position peaked at $7K in Q1 2021.
109 funds tracked by Wall St. Rank held Altimmune as of Q2 2021.

Based on Central Trust Company's 13F filing for Q2 2021, filed 23 Jul 2021.